Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000492687 | SCV000580761 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-12-17 | criteria provided, single submitter | clinical testing | The c.1357_1363delGGGTGTG pathogenic mutation, located in coding exon 9 of the FLCN gene, results from a deletion of 7 nucleotides at nucleotide positions 1357 to 1363, causing a translational frameshift with a predicted alternate stop codon (p.G453Rfs*13). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV001044760 | SCV001208575 | pathogenic | Birt-Hogg-Dube syndrome | 2023-03-26 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gly453Argfs*13) in the FLCN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FLCN are known to be pathogenic (PMID: 15852235). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FLCN-related conditions. ClinVar contains an entry for this variant (Variation ID: 428658). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002481559 | SCV002787532 | likely pathogenic | Birt-Hogg-Dube syndrome; Familial spontaneous pneumothorax; Potocki-Lupski syndrome; Nonpapillary renal cell carcinoma; Colorectal cancer | 2021-10-13 | criteria provided, single submitter | clinical testing |